Intelligence Β· Patent portfolio
United Therapeutics Europe Patents
Full USPTO pharma patent portfolio for United Therapeutics Europe β grant dates, expiration, and drug cross-links.
- Patents
- 3,720
- Expiring β€24m
- 234
Quick answer
United Therapeutics Europe has 3,720 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 234 expire within 24 months β use filters for patent-cliff planning.
-
US 7989501
Treating renal cancer using a 4-[bis[2-[(methylsulfonyl)oxy]ethyl]amino]-benzaldehyde
granted -
US 7981610
ZAP-70 expression as a marker for chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL/SLL)
granted -
US 7982011
Mutated anti-cd22 antibodies and immunoconjugates
granted -
US 7981409
Method of reducing aging of skin by applying interleukin-1 alpha
granted -
US 7976832
Active topical skin protectants containing amines, polyalkenimines and /or derivatives
granted -
US 7977468
Chromosome 3p21.3 genes are tumor suppressors
granted -
US 7972606
T24 antigen for immunodiagnosis of Taenia solium cysticercosis
granted -
US 7973057
Thalidomide analogs
granted -
US 7973020
Compositions and methods for inhibiting expression of a gene from the ebola virus
granted -
US 7972821
Production of functional proteins: balance of shear stress and gravity
granted -
US 7968664
Nitric oxide-releasing diazeniumdiolated acrylonitrile-based polymers, and compositions, medical devices, and uses thereof
granted -
US 7968298
Use of herpesviruses, herpesvirus proteins and nucleic acids encoding the proteins to inhibit CCR5-tropic HIV-1 infection and replication
granted -
US 7968117
Externally triggered microcapsules
granted -
US 7964559
MVL, an antiviral protein from a cyanobacterium
granted -
US 7964576
Anti-arthropod vector vaccines, methods of selecting and uses thereof
granted -
US 7960535
Recombinant lipidated PsaA protein, methods of preparation and use
granted -
US 7960356
Oligodeoxynucleotide and its use to induce an immune response
granted -
US 7959929
Materials and methods for respiratory disease control in canines
granted -
US 7959934
Method for rapid generation of mature dendritic cells
granted -
US 7956086
Methods for the formulation and manufacture of artesunic acid for injection
granted -
US 7951786
Method of treating inflammatory arthropathies with suppressors of CpG oligonucleotides
granted -
US 7951579
Method for bacteriophage delivery and amplification
granted -
US 7951390
Slow-release microcapsule composition for safe delivery of agriculturally active material
granted -
US 7951383
Attenuated parainfluenza virus (PIV) vaccines
granted -
US 7951817
Pyridomorphinans, pyridazinomorphinans and use thereof
granted -
US 7951909
Immunogenic peptide composition comprising a promiscuous helper T cell epitope and an N-terminal fragment of AΞ²1-42 peptide
granted -
US 7947289
Multimeric protein toxins to target cells having multiple identifying characteristics
granted -
US 7947651
Secreted frizzled related protein, sFRP, fragments and methods of use thereof
granted -
US 7947822
HIV vaccines based on Env of multiple clades of HIV
granted -
US 7943318
Microrna-based methods and compositions for the diagnosis, prognosis and treatment of lung cancer
granted -
US 7943148
Amino acid sites in Flavivirus E proteins useful for development of diagnostics and vaccines
granted -
US 7943775
Small molecules for imaging protein-protein interactions
granted -
US 7943159
Female sex pheromone of the dogwood borer (DWB), Synanthedon scitula, and attraction inhibitor (antagonist)
granted -
US 7939639
Functional role of adrenomedullin (AM) and the gene related product (PAMP) in human pathology and physiology
granted -
US 7939635
Autotaxin: motility stimulating protein useful in cancer diagnosis and therapy
granted -
US 7935351
Use of CPG oligodeoxynucleotides to induce angiogenesis
granted -
US 7932096
Trioxyethylene gold nanoclusters functionalized with a single DNA
granted -
US 7931919
Method of producing glycine-stabilized, lyophilized plasma
granted -
US 7932074
Multivalent human-bovine rotavirus vaccine
granted -
US 7928194
Recombinant antigen for diagnosis and prevention of murine typhus
granted -
US 7928096
Polydiazeniumdiolated cyclic polyamines with polyphasic nitric oxide release and related compounds, compositions comprising same and methods of using same
granted -
US 7928079
Polysaccharide-derived nitric oxide-releasing carbon-bound diazeniumdiolates
granted -
US 7927793
Cell lines and host nucleic acid sequences related to infectious disease
granted -
US 7923535
Tryptophan as a functional replacement for ADP-ribose-arginine in recombinant proteins
granted -
US 7919104
Functional epitopes of Streptococcus pneumoniae PsaA antigen and uses thereof
granted -
US 7919607
Nucleic acids encoding humanized anti-tag 72 CC49 antbodies
granted -
US 7919477
Multiple CpG oligodeoxynucleotides and their use to induce an immune response
granted -
US 7919301
Recovery of recombinant human parainfluenza virus type 2 (HPIV2) from CDNA and use of recombinant HPIV2 in immunogenic compositions and as vectors to elicit immune responses against PIV and other human pathogens
granted
Frequently asked questions
How many patents does United Therapeutics Europe have?
3,720 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do United Therapeutics Europe patents expire?
234 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.
Where does this data come from?
USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.
Data attribution: Data sources Β· Patent directory